Salix Pharmaceuticals (SLXP +7.3%) shares surge after Q4 results topped expectations and sales...

|About: Salix Pharmaceuticals, Ltd. (SLXP)|By:, SA News Editor

Salix Pharmaceuticals (SLXP +7.3%) shares surge after Q4 results topped expectations and sales of its Xifaxan gastrointestinal drug picked up significantly during H2 2011. SLXP also guides to at least 25% organic growth in Xifaxan in 2012, with strong growth in January that beat the prior record month of December.